Low growth temperatures improve the conformational quality of aggregation prone recombinant proteins in both soluble and insoluble E. coli cell fractions
© Vera et al; licensee BioMed Central Ltd. 2006
Published: 10 October 2006
Protein aggregation is a major bottleneck in the bacterial production of recombinant proteins. Among others, induction of gene expression at suboptimal growth temperatures (for instance, below 37°C in Escherichia coli), has been repeatedly observed as a convenient procedure to enhance the solubility of aggregation-prone proteins and to minimize inclusion body formation. However, the effect of low growth temperatures in protein features, other than mere solubility, has been rarely explored.
In this work, we have determined the folding status and functionality of an engineered GFP variant when produced at 37, 30 and 16°C. The strain used was BL21 (DE3) and the plasmid pET21-b(+). Gene expression was induced by IPTG using different production times for each temperature: 2 h at 37°C, 5 h at 30°C and 16 h at 16°C, which are equivalent to the same biomass increase.
As expected, solubility of a recombinant GFP was largely improved at low temperatures. On the other hand, and very interestingly, the quality of GFP, as reflected by its specific fluorescence emission, was largely enhanced at 16°C not only in the soluble cell fraction but also in the residual inclusion bodies. This intriguing observation indicates that the physicochemical conditions governing protein folding act in parallel on both soluble and aggregated protein forms. Therefore, protein misfolding and aggregation are clearly not coincident events, what strongly supports the hypothesis that incorrect folding is not a straightforward cause of protein deposition.
This work has been funded by BIO2004-00700 from MEC, Spain and 2005GR-00956 (AGAUR). Andrea Vera Barrón is recipient of a doctoral fellowship from UAB, Spain, Núria González-Montalbán and Elena Garcia-Fruitós are recipients of a doctoral fellowships from MEC, Spain.
This article is published under license to BioMed Central Ltd.